Neumora Therapeutics NMRA
NASDAQ NMRA
$0.40 -0.01 (-3.00%)
As of: Oct 22, 2026 · 11:05 AM EDT

Neumora Therapeutics (NMRA) Amortization of Deferred Charges (2025 - 2026)

Updated

Analysis

Neumora Therapeutics (NMRA) Amortization of Deferred Charges (2025 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,171.06 Bn 1,139.65 Bn 19.71 Bn
2 Johnson & Johnson 634.89 Bn 553.42 Bn 17.26 Bn
3 AbbVie 503.32 Bn 476.44 Bn 12.70 Bn
4 Merck 377.44 Bn 331.82 Bn 12.21 Bn
5 Novartis Ag 303.91 Bn 267.90 Bn 11.24 Bn
6 Astrazeneca 267.03 Bn 240.72 Bn 12.86 Bn
7 Amgen 241.88 Bn 197.28 Bn 7.24 Bn
8 Gilead Sciences 194.01 Bn 168.20 Bn 6.22 Bn
9 Pfizer 172.57 Bn 119.21 Bn 10.94 Bn
10 Neumora Therapeutics 74.97 Mn -542.99 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 394,000.00
Mar 31, 2026 418,000.00
Jun 30, 2025 303,000.00
API Access

Neumora Therapeutics Amortization of Deferred Charges API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=amortization-of-deferred-charges&ticker=NMRA&period=max&api_key=YOUR_API_KEY